Holen Sie sich die Stockscreener-App
163.02
2.89%
4.58
Handel nachbörslich:
162.75
-0.27
-0.17%
Schlusskurs vom Vortag:
$158.44
Offen:
$158.46
24-Stunden-Volumen:
1.50M
Relative Volume:
1.10
Marktkapitalisierung:
$22.26B
Einnahmen:
$1.53B
Nettoeinkommen (Verlust:
$-214.69M
KGV:
-92.62
EPS:
-1.76
Netto-Cashflow:
$-43.68M
1W Leistung:
+7.29%
1M Leistung:
+8.79%
6M Leistung:
-5.98%
1J Leistung:
+33.35%
1-Tages-Spanne:
$157.84
$163.87
1-Wochen-Bereich:
$149.38
$163.87
52-Wochen-Spanne:
$110.57
$183.00
Natera Inc Stock (NTRA) Company Profile
Firmenname
Natera Inc
Sektor
Branche
Telefon
650-249-9090
Adresse
13011 MCCALLEN PASS, AUSTIN, CA
Vergleichen Sie NTRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
163.02 | 21.75B | 1.53B | -214.69M | -43.68M | -1.76 |
|
TMO
Thermo Fisher Scientific Inc
|
489.01 | 183.16B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
210.93 | 150.53B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
650.84 | 52.32B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
119.20 | 33.77B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.09 | 32.20B | 15.50B | 1.33B | 2.16B | 7.34 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-08 | Fortgesetzt | Craig Hallum | Buy |
| 2024-02-20 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-11-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Eingeleitet | Stephens | Overweight |
| 2022-03-08 | Eingeleitet | Goldman | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-09-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-09-17 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-05-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Eingeleitet | JP Morgan | Neutral |
| 2018-07-05 | Bestätigt | Piper Jaffray | Overweight |
| 2017-08-07 | Bestätigt | Morgan Stanley | Overweight |
| 2016-11-10 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-11 | Bestätigt | The Benchmark Company | Buy |
| 2016-04-19 | Eingeleitet | The Benchmark Company | Buy |
| 2015-09-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2015-08-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2015-07-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-07-27 | Eingeleitet | Wedbush | Neutral |
Alle ansehen
Natera Inc Aktie (NTRA) Neueste Nachrichten
Natera (NTRA) Is Up 7.3% After Launching Fetal Focus and Raising 2025 Revenue Guidance - simplywall.st
What is Natera Inc. s revenue forecastQuarterly Portfolio Summary & Weekly Top Stock Performers List - thegnnews.com
Natera president sells $136k in stock By Investing.com - Investing.com Nigeria
Natera: President Fesko sells $105k in shares By Investing.com - Investing.com Canada
Natera: President Fesko sells $105k in shares - Investing.com
Natera president sells $136k in stock - Investing.com
Natera Surges 2.89% on $240M Volume as Institutional Buyers Pile In Stock Ranks 423rd in Market Activity Amid Analyst Upgrades - AInvest
LabCorp Fails to Block Natera Patent-Invalidity Claims Pre-Trial - Bloomberg Law News
Can Natera Inc. Regain Momentum After Breakdown2025 Winners & Losers & Advanced Technical Analysis Signals - beatles.ru
Natera’s Strong Growth Potential and Market Leadership Justify Buy Rating - TipRanks
Natera Inc. Pullback Analyzed — Is It Time to ExitJuly 2025 EndofMonth & Fast Entry Momentum Trade Alerts - sundaytimes.kr
Non-invasive Prenatal Testing Market Set to Witness Massive - openPR.com
Natera price target raised to $195 from $185 at Morgan Stanley - MSN
Compared to Estimates, Natera (NTRA) Q2 Earnings: A Look at Key Metrics - MSN
5 Revealing Analyst Questions From Natera’s Q2 Earnings Call - Yahoo Finance
Natera (NTRA) Q2 Results: 32% Revenue Growth, Strong Buy RatingNews and Statistics - IndexBox
Natera Q2 Earnings Call Highlights Strong Growth, Raises Revenue Guidance and Announces New Product Launches and Innovations - AInvest
1 ‘Strong Buy’ Stock Analysts Think Will Soar 62% - Yahoo Finance
Natera (NTRA) Is Up 14.1% After Raising Revenue Guidance and Launching New Prenatal Test – Has the Bull Case Changed? - simplywall.st
Natera Insider Sold Shares Worth $958,059, According to a Recent SEC Filing - MarketScreener
Natera director Sheena Jonathan sells $958k in NTRA stock - Investing.com
Natera director Sheena Jonathan sells $958k in NTRA stock By Investing.com - Investing.com Australia
Natera Inc. Reports Strong Growth and Strategic Advances - TipRanks
Natera at Canaccord Conference: Growth and Innovation in Focus - Investing.com
Natera at Canaccord Conference: Growth and Innovation in Focus By Investing.com - Investing.com Australia
Natera Surges 1.76% on $290M Volume, Climbs to 356th in Market Activity - AInvest
How clinicogenomic data are reshaping kidney disease trials and drug discovery - Nature
New noninvasive prenatal test can screen for CF, other genetic diseases - Cystic Fibrosis News Today
Leerink Partners Maintains Natera(NTRA.US) With Buy Rating, Announces Target Price $235 - 富途牛牛
NTRA Q2 Deep Dive: Oncology Growth, Product Innovation, and Margin Pressures - TradingView
Natera Surges 3.35% as Daily Volume Slumps 49.12% to 310M Dollar Ranking 335th in Market Activity - AInvest
Natera Stock Jumps 13.69% In 3 Days As Technicals Signal Bullish Reversal - AInvest
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cytek Biosciences (CTKB), Natera (NTRA) and Warby Parker (WRBY) - The Globe and Mail
Natera: Piper Sandler Raises PT to $220 from $210, Maintains Overweight - AInvest
Natera And 2 Other Stocks That May Be Priced Below Their Estimated Value - Yahoo Finance
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates - MSN
Mixed Analyst Opinions on Healthcare Stocks Cytek Biosciences, Natera, and Warby Parker - AInvest
Natera introduces prenatal test for detecting inherited conditions - MSN
Natera raises revenue guidance to $2.1B and targets margin expansion through AI-driven efficiencies - MSN
Evercore Gives Natera (NTRA) Outperform Rating - MSN
Natera's Signatera test to be covered under Medicare - MSN
How much upside does Natera Inc. haveAnalyst Upgrade Watch - thegnnews.com
What is the Moat Score of Natera Inc.Free Growth Stock Screener - mustnews.co.kr
Natera Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Natera, Inc. (NASDAQ:NTRA) Q2 2025 Earnings Call Transcript - Insider Monkey
What technical models suggest about Natera Inc.’s comebackFree Secure Capital Picks With Upside Potential - Newser
14 Best Aggressive Growth Stocks to Buy According to Analysts - Insider Monkey
Natera shares surge 17% after strong Q2 results and upgraded guidance - Invezz
Natera Stock: Growth or Bubble? - StocksToTrade
Natera Inc. Stocks Soar After Impressive Q2 Results - timothysykes.com
Natera’s Stock Leaps Amid Clinical Trial Success - StocksToTrade
Finanzdaten der Natera Inc-Aktie (NTRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Natera Inc-Aktie (NTRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Fesko John | PRESIDENT, CHIEF BUS. OFFICER |
Aug 14 '25 |
Sale |
155.46 |
678 |
105,401 |
152,747 |
| Sheena Jonathan | CO-FOUNDER |
Aug 08 '25 |
Sale |
161.90 |
3,070 |
497,047 |
242,252 |
| Sheena Jonathan | CO-FOUNDER |
Aug 11 '25 |
Sale |
153.67 |
3,000 |
461,012 |
34,282 |
| Chapman Steven Leonard | CEO AND PRESIDENT |
Aug 01 '25 |
Sale |
132.88 |
5,807 |
771,656 |
163,593 |
| Marcus Gail Boxer | Director |
Aug 01 '25 |
Sale |
133.17 |
2,496 |
332,395 |
5,763 |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS |
Aug 01 '25 |
Sale |
132.89 |
3,000 |
398,657 |
123,059 |
0.32%
0.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):